In addition, the EGFR T790M subclone can not only resist first- and second-generation EGFR inhibitors, but also promote resistance to EGFR inhibitors in NSCLC patients who are treated for the first time (Piotrowska et al., 2015). This evidence concerns the gene EGFR and non-small cell lung carcinoma.